2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P991654
    SAR228810 98%
    SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research.
    SAR228810
  • HY-P991755
    Anti-Rat CD47 Antibody (OX-101) 98%
    Anti-Rat CD47 Antibody (OX-101) reacts with CD47. Anti-Rat CD47 Antibody (OX-101) accelerates hematoma clearance and alleviates hydrocephalus after experimental intraventricular hemorrhage. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-Rat CD47 Antibody (OX-101)
  • HY-P991791
    Anti-Rat CD11b/c Antibody (OX42) 98%
    Anti-Rat CD11b/c Antibody (OX42) reacts with rat CD11b and CD11c. Anti-Rat CD11b/c Antibody (OX42) inhibits complement-mediated rosettes formation and leukocyte migration in vitro, and blocks the binding of iC3b to CR3 in vitro and in vivo. Recommend Isotype Controls: Mouse IgG2a kappa, Isotype Control (HY-P99978).
    Anti-Rat CD11b/c Antibody (OX42)
  • HY-P991866
    BI 1034020 98%
    BI 1034020 is a humanized nanobody, targeting two different epitopes of Aβ ( Aβ40 and Aβ42) with high affinity. BI 1034020 reduces the level of free Ab peptide in plasma and thus prevent the formation of new Aβ plaques and clear existing plaques. BI 1034020 can be used for Alzheimer’s disease research.
    BI 1034020
  • HY-P991867
    SHR-1707 98%
    SHR-1707 is a humanized anti-Aβ IgG1 monoclonal antibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    SHR-1707
  • HY-P991869
    Aquaporumab 98%
    Aquaporumab (AQmabAM) is an engineered human monoclonal IgG antibody. Aquaporumab is a selective inhibitor of aquaporin 4 (AQP4), binding tightly to AQP4 and competitively displacing AQP4-IgG from serum [1][2]. Aquaporumab significantly reduces neuromyelitis optica lesions in spinal cord slice cultures and in mice receiving intracerebral injection of AQP4-IgG and complement [1][2]. Aquaporumab can be used for research on neuromyelitis optica spectrum disorders [1][2]."}
    Aquaporumab
  • HY-P991945
    Anti-CNTFR Antibody 98%
    Anti-CNTFR Antibody is an antibody against human CNTFR. Recommend Isotype Controls:?Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Anti-CNTFR Antibody
  • HY-P991957
    PRN100 98%
    PRN100 is a fully humanized monoclonal antibody against cellular prion protein (PrPᶜ), belonging to the IgG4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 is designed to prevent cellular prion protein from being recruited and converted into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the study of Creutzfeldt-Jakob disease.
    PRN100
  • HY-P992012
    CA1001 98%
    CA1001 is a small-molecule ZNF74 inhibitor and a peripherally restricted κ/δ dual opioid receptor agonist. CA1001 exhibits potent antitumor activity both in vitro and in vivo. CA1001, in combination with immune checkpoint inhibitors, significantly enhances tumor regression. CA1001 activates peripherally restricted κ/δ dual opioid receptors and exerts analgesic effects under conditions of inflammatory pain, neuropathic pain, and mechanical hyperalgesia. CA1001 can be used in research related to melanoma, mechanical hyperalgesia, neuropathic pain, and inflammatory arthritis pain.
    CA1001
  • HY-P992057
    Armanezumab 98%
    Armanezumab is a monoclonal antibody that targets and inhibits tau protein, and it specifically binds to the exposed N-terminal domain of pathological tau protein. Armanezumab can be used in relevant studies on Alzheimer's disease, frontotemporal dementia, and Pick's disease.
    Armanezumab
  • HY-P992157
    Anti-APP/Amyloid beta Antibody (3D6) 98%
    Anti-APP/Amyloid beta Antibody (3D6) is an antibody targeting β-amyloid protein (Aβ) containing free Asp1. Anti-APP/Amyloid beta Antibody (3D6) recognizes and binds to the amino acid epitope at positions 1-5 of β-amyloid protein with a free Asp1 residue. Anti-APP/Amyloid beta Antibody (3D6) serves as a detection antibody in immunoblot analysis. Anti-APP/Amyloid beta Antibody (3D6) is applicable to research related to Alzheimer's disease.
    Anti-APP/Amyloid beta Antibody (3D6)
  • HY-P992171
    ADCT-701 Antibody 98%
    ADCT-701 Antibody is a humanized IgG1 antibody against hDLK-1 and an ADC antibody. ADCT-701 Antibody can be conjugated with the PBD dimer cytotoxin SG3199 (HY-101161) via the cleavable Val-Ala (HY-W007035) linker to construct the ADC ADCT-701. ADCT-701 Antibody can be used in the research of neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and rhabdomyosarcoma.
    ADCT-701 Antibody
  • HY-P992172
    ADEL-Y01 98%
    ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonal antibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies.
    ADEL-Y01
  • HY-P992223
    Anti-DAG1/Dystroglycan Antibody (DAG-6F4) 98%
    Anti-DAG1/Dystroglycan Antibody (DAG-6F4) is a human monoclonal antibody against DAG1/Dystroglycan. Anti-DAG1/Dystroglycan Antibody (DAG-6F4) can bind specifically to the α and β subunits of the dystroglycan protein complex. Anti-DAG1/Dystroglycan Antibody (DAG-6F4) is applicable to research related to muscular dystrophy.
    Anti-DAG1/Dystroglycan Antibody (DAG-6F4)
  • HY-P992275
    Anti-Nicastrin Antibody (A5226A) 98%
    Anti-Nicastrin Antibody (A5226A) is a monoclonal antibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease.
    Anti-Nicastrin Antibody (A5226A)
  • HY-P992345
    DS002 98%
    DS002 is a human monoclonal antibody targeting NGF/bNGF, with an IC50 of 6.60 nM against human NGF, 1.98 nM against rat NGF, and 8.46 nM against mouse NGF. DS002 blocks NGF-TrkA binding, interrupts pain signal transduction, inhibits TrkA-mediated downstream signaling pathways, and alters aromatic amino acid metabolic pathways. DS002 inhibits cancer cell proliferation. DS002 exerts a preventive effect on Paclitaxel-, Cisplatin- and Vincristine-induced peripheral neuropathy in rats. DS002 can be used in studies related to chronic pain and chemotherapy-induced peripheral neuropathy.
    DS002
  • HY-P992360
    GT-002 98%
    GT-002 is a partial positive allosteric modulator targeting the α3 subtype of GABAA receptors, as well as a specific binder of tumor-associated TF-glycosylated LYPD3. GT-002 mildly enhances GABA-induced chloride currents by binding to the benzodiazepine site of GABAA receptors, thereby alleviating prefrontal hypofunction and improving cognitive, memory and social interaction abilities. GT-002 can be used in research related to schizophrenia spectrum disorders, various squamous cell carcinomas, colorectal cancer, non-small cell lung cancer, and aromatic L-amino acid decarboxylase deficiency.
    GT-002
  • HY-P992380
    IBC-Ab002 98%
    IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease.
    IBC-Ab002
  • HY-P992382
    IC 100 98%
    IC 100 is a humanized IgG4κ monoclonal antibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003.
    IC 100
  • HY-P992400
    Lu AF87908 98%
    Lu AF87908 is an IgG1 monoclonal antibody targeting the p-Ser396/404 epitope of tau protein, which mainly binds to the pSer396 region. Lu AF87908 can be used in the research of Alzheimer's disease. The recommended isotype control is human IgG1 kappa (HY-P99001).
    Lu AF87908
Cat. No. Product Name / Synonyms Application Reactivity